Revolution Medicines Target of Unusually Large Options Trading (NASDAQ:RVMD)

Revolution Medicines, Inc. (NASDAQ:RVMD) saw unusually large options trading on Friday. Stock traders bought 12,797 put options on the stock. This is an increase of approximately 131% compared to the average volume of 5,546 put options.

Insider Buying and Selling

In other news, CFO Jack Anders sold 2,753 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $273,868.44. Following the completion of the sale, the chief financial officer directly owned 125,512 shares of the company’s stock, valued at approximately $12,485,933.76. This represents a 2.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Stephen Michael Kelsey sold 4,302 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $427,962.96. Following the transaction, the insider owned 295,398 shares in the company, valued at approximately $29,386,193.04. This trade represents a 1.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 149,592 shares of company stock valued at $15,010,732 in the last 90 days. Company insiders own 8.20% of the company’s stock.

Hedge Funds Weigh In On Revolution Medicines

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in shares of Revolution Medicines by 6.7% in the fourth quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock valued at $1,331,739,000 after purchasing an additional 1,056,792 shares during the last quarter. Farallon Capital Management LLC lifted its position in shares of Revolution Medicines by 2.1% in the third quarter. Farallon Capital Management LLC now owns 14,625,692 shares of the company’s stock valued at $683,020,000 after acquiring an additional 300,000 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Revolution Medicines by 8.3% during the fourth quarter. Janus Henderson Group PLC now owns 12,303,502 shares of the company’s stock valued at $980,036,000 after acquiring an additional 947,448 shares during the last quarter. Baker BROS. Advisors LP raised its stake in Revolution Medicines by 1.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 9,455,357 shares of the company’s stock valued at $441,565,000 after purchasing an additional 90,385 shares during the last quarter. Finally, Nextech Invest Ltd. raised its stake in Revolution Medicines by 20.7% in the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after purchasing an additional 1,304,347 shares during the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.

Revolution Medicines Price Performance

Shares of RVMD traded down $2.14 during trading hours on Friday, reaching $97.15. The company had a trading volume of 384,525 shares, compared to its average volume of 3,437,770. The company has a market capitalization of $19.25 billion, a price-to-earnings ratio of -16.45 and a beta of 0.99. Revolution Medicines has a 12-month low of $29.17 and a 12-month high of $124.49. The firm has a 50 day simple moving average of $103.42 and a 200-day simple moving average of $76.40. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.16.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30). During the same quarter in the prior year, the business posted ($1.12) EPS. Research analysts expect that Revolution Medicines will post -3.49 earnings per share for the current year.

Key Headlines Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Large institutional buying and heavy ownership from firms (General Atlantic, Norges Bank, Avoro, UBS, Polar Capital) signals strong long-term conviction from major investors, which can provide floor support for the share price. Institutional Summary
• Positive Sentiment: Analyst coverage is broadly positive — recent upgrades/initiations (Evercore, UBS, Wedbush, Benchmark) and a consensus “Buy” tilt may attract buyer interest and help stabilize the stock over time. Analyst Coverage
• Neutral Sentiment: Company profile — clinical-stage biotech focused on RAS-pathway oncology (RMC-4630, RMC-6291, RMC-6236). High upside if trials read out well, but clinical/readout risk is intrinsic. Company Profile
• Neutral Sentiment: Recent earnings (Feb. 25) missed estimates (EPS -$1.86 vs. -$1.56 consensus), underscoring continued cash burn and negative EPS expectations for the year — a typical headwind for a development-stage biotech. Earnings Summary
• Negative Sentiment: Multiple senior insiders sold shares on March 17 (largest: Mark Goldsmith 12,871 sh; COO Margaret Horn 4,583 sh; CFO Jack Anders 2,753 sh; plus smaller sales by others) at ~ $99.48 — sizable insider selling can weigh on sentiment and intra-day liquidity. SEC filings: Goldsmith SEC Filing · Horn SEC Filing
• Negative Sentiment: Insider sales by multiple executives (Xiaolin Wang, Lin Wei and others) collectively reduce insider ownership stakes and may be read as liquidity-taking by insiders, pressuring near-term sentiment. SEC filings: Wang SEC Filing · Wei SEC Filing

Analyst Ratings Changes

Several brokerages have recently weighed in on RVMD. Benchmark reiterated an “overweight” rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. Jefferies Financial Group began coverage on Revolution Medicines in a research report on Monday. They issued a “buy” rating on the stock. Wedbush reaffirmed an “outperform” rating on shares of Revolution Medicines in a research report on Friday, January 9th. Evercore raised Revolution Medicines to a “strong-buy” rating in a report on Wednesday, February 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $78.94.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.